SCHEMBL4159550

SCHEMBL4159550

N#Cc1ccc2c(-c3cc4cc(CN5CCOCC5)ccc4[nH]3)n[nH]c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 19/20 1.00
CDK7 P50613 14/20 1.00
ITK Q08881 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4161756 0.90 CHEK1 (0.82) CHEK1CDK7ITK
SCHEMBL13655140 0.87 CHEK1 (0.78) CHEK1CDK7
SCHEMBL5051793 0.87 CHEK1 (0.77) CHEK1CDK7ITK
SCHEMBL5051866 0.87 CHEK1 (0.84) CHEK1CDK7ITK
SCHEMBL5058882 0.87 CHEK1 (0.81) CHEK1CDK7ITK
SCHEMBL5054073 0.85 CHEK1 (1.00) CHEK1CDK7ITK
SCHEMBL5055674 0.85 CHEK1 (0.75) CHEK1CDK7ITK
SCHEMBL4164607 0.85 CHEK1 (1.00) CHEK1CDK7ITK
SCHEMBL13655139 0.85 CHEK1 (0.75) CHEK1CDK7
SCHEMBL13655147 0.85 CHEK1 (0.75) CHEK1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101115724-A Inhibitors of checkpoint kinases MERCK & CO INC (US) 2008-01-30 CN claimed
US-20080004259-A1 Inhibitors of Checkpoint Kinases MERCK & CO., INC. 2008-01-03 US claimed
CN-101440092-B 2-indazole-4-aza indole-5-amino derivatives, and preparation and use thereof UNIV ZHEJIANG 2010-11-17 CN disclosed
US-20090247504-A1 Indazole Derivatives for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LIMITED (GB) 2009-10-01 US disclosed
US-20090247504-A1 Indazole Derivatives for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LIMITED (GB) 2009-10-01 US disclosed
US-20090192155-A1 Identification of Compounds Suitable for Treating Ad MERCK SHARP & DOHME LIMITED (GB) 2009-07-30 US disclosed
CN-101440092-A 2-indazole-4-aza indole-5-amino derivatives, and preparation and use thereof UNIV ZHEJIANG (CN) 2009-05-27 CN disclosed
EP-1983979-A1 IDENTIFICATION OF COMPOUNDS SUITABLE FOR TREATING AD Merck Sharp & Dohme Limited (GB) 2008-10-29 EP disclosed
CN-101115724-A Inhibitors of checkpoint kinases MERCK & CO INC (US) 2008-01-30 CN disclosed
US-20080004259-A1 Inhibitors of Checkpoint Kinases MERCK & CO., INC. 2008-01-03 US disclosed
EP-1851203-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2007-11-07 EP disclosed
WO-2007088400-A1 IDENTIFICATION OF COMPOUNDS SUITABLE FOR TREATING AD MERCK SHARP & DOHME LIMITED (GB) 2007-08-09 WO disclosed
WO-2006086255-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247504-A1 Indazole Derivatives for Treatment of Alzheimer's Disease MAPT, PSEN2, PSEN1 CHEK1 1733/4885CDK7 281/4885ITK 1958/4885
US-20090192155-A1 Identification of Compounds Suitable for Treating Ad PSEN2, MAPT, PSEN1 CHEK1 2578/4885CDK7 413/4885ITK 4578/4885
US-20080004259-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B CHEK1 1/4885CDK7 43/4885ITK 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.